Use of cytokine polymorphisms and Epstein - Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients

Clinical Transplantation

Volumn 20, Issue 3, 2006, Pages 389-393

  Lee, Timothy C ^a   Savoldo, Barbara ^b   Barshes, Neal R ^a   Rooney, Cliona M ^b   Heslop, Helen E ^b   Gee, Adrian P ^b   Caldwell, Yvette ^b   Scott, Jaymee D ^a   Goss, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cytokine polymorphism; Epstein Barr virus; Post transplant lymphoproliferative disorder

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; DRUG DOSE REGIMEN; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GENETIC CODE; GENOTYPE; GRAFT RECIPIENT; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; LYMPHOPROLIFERATIVE DISORDERS; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 33745083737     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00498.x     Document Type: Article

References (15)

1. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998: 2: 56.
2. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis, and management. Pediatr Transplant 2002: 6: 280.
3. Younes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000: 70: 94.
4. Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000: 70: 593.
5. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005: 5: 2222.
6. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004: 103: 3979.
7. Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005: 5: 566.
8. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993: 91: 2806.
9. Randhawa P, Nalesnik M, Demetris J, Zeevi A. Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease. Hematol Oncol 1995: 13: 13.
10. Van Buskirk AM, Malik V, Xia D, Pelletier RP. A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplant Proc 2001: 33: 1834.
11. Savoldo B, Huls MH, Liu Z et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002: 100: 4059.
12. John S, Turner D, Donn R et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenetics 25: 419.
13. Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001: 97: 1165.
14. Carpentier L, Tapiero B, Alvarez F, Viau C, Lafieri C. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis 2003: 88: 1853.
15. Callan MF, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 1998: 187: 1395.